Suppr超能文献

幽门螺杆菌(Helicobacter pylori)在对青霉素过敏的患者中的一线和挽救治疗:来自欧洲幽门螺杆菌管理登记处(Hp-EuReg)的经验。

Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg).

机构信息

Gastroenterology Unit, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Investigación Sanitaria Princesa (IIS-IP), Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Madrid, Spain.

Digestive Unit, Agencia Sanitaria Costa del Sol, Marbella, Spain.

出版信息

Helicobacter. 2020 Jun;25(3):e12686. doi: 10.1111/hel.12686. Epub 2020 Mar 16.

Abstract

BACKGROUND

Experience in Helicobacter pylori eradication treatment of patients allergic to penicillin is very scarce. A triple combination with a PPI, clarithromycin (C), and metronidazole (M) is often prescribed as the first option, although more recently the use of a quadruple therapy with PPI, bismuth (B), tetracycline (T), and M has been recommended.

AIM

To evaluate the efficacy and safety of first-line and rescue treatments in patients allergic to penicillin in the "European Registry of H pylori management" (Hp-EuReg).

METHODS

A systematic prospective registry of the clinical practice of European gastroenterologists (27 countries, 300 investigators) on the management of H pylori infection. An e-CRF was created on AEG-REDCap. Patients with penicillin allergy were analyzed until June 2019.

RESULTS

One-thousand eighty-four patients allergic to penicillin were analyzed. The most frequently prescribed first-line treatments were as follows: PPI + C + M (n = 285) and PPI + B + T + M (classic or Pylera ; n = 250). In first line, the efficacy of PPI + C + M was 69%, while PPI + B + T + M reached 91% (P < .001). In second line, after the failure of PPI + C + M, two rescue options showed similar efficacy: PPI + B + T + M (78%) and PPI + C + levofloxacin (L) (71%) (P > .05). In third line, after the failure of PPI + C + M and PPI + C + L, PPI + B + T + M was successful in 75% of cases.

CONCLUSION

In patients allergic to penicillin, a triple combination with PPI + C + M should not be generally recommended as a first-line treatment, while a quadruple regimen with PPI + B + T + M seems to be a better option. As a rescue treatment, this quadruple regimen (if not previously prescribed) or a triple regimen with PPI + C + L could be used but achieved suboptimal (<80%) results.

摘要

背景

在对青霉素过敏的患者中,幽门螺杆菌(H.pylori)根除治疗的经验非常有限。质子泵抑制剂(PPI)、克拉霉素(C)和甲硝唑(M)三联疗法通常被作为首选方案,但最近也推荐使用 PPI、枸橼酸铋(B)、四环素(T)和 M 的四联疗法。

目的

在“欧洲 H.pylori 管理登记处(Hp-EuReg)”中评估对青霉素过敏患者的一线和补救治疗的疗效和安全性。

方法

这是一项针对欧洲胃肠病学家临床实践的系统性前瞻性登记研究(27 个国家,300 名调查员),涉及 H.pylori 感染的管理。在 AEG-REDCap 上创建了电子病例报告表(e-CRF)。直到 2019 年 6 月,对青霉素过敏的患者进行了分析。

结果

共分析了 1084 例对青霉素过敏的患者。最常开的一线治疗方案如下:PPI+C+M(n=285)和 PPI+B+T+M(经典或 Pylera;n=250)。在一线治疗中,PPI+C+M 的疗效为 69%,而 PPI+B+T+M 则达到 91%(P<.001)。二线治疗中,在 PPI+C+M 失败后,两种补救方案的疗效相似:PPI+B+T+M(78%)和 PPI+C+左氧氟沙星(L)(71%)(P>.05)。三线治疗中,在 PPI+C+M 和 PPI+C+L 失败后,PPI+B+T+M 成功的比例为 75%。

结论

在对青霉素过敏的患者中,不建议将 PPI+C+M 三联疗法作为一线治疗方案,而 PPI+B+T+M 四联疗法似乎是更好的选择。作为补救治疗,如果未使用过,可使用该四联方案(如果未使用过)或 PPI+C+L 的三联方案,但疗效欠佳(<80%)。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验